drugset / Trial / NCT02157506

A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure

NCT02157506

RandomizedParallel-groupTriple-blindTreatment

Summary

A randomized, double-blinded, placebo-controlled study of continuous 6-hour IV infusions of CXL-1427 in hospitalized patients with systolic heart failure.

Timeline

Start
2014-06-30
Primary completion
2015-05-31
Completion
2015-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject cimlanod Other / unclassified 3 ug/kg Intravenous

Indications